Dependence on the MUC1-C Oncoprotein in Non-Small Cell Lung Cancer Cells

被引:141
作者
Raina, Deepak [3 ]
Kosugi, Michio [1 ]
Ahmad, Rehan [1 ]
Panchamoorthy, Govind [3 ]
Rajabi, Hasan [1 ]
Alam, Maroof [1 ]
Shimamura, Takeshi [1 ]
Shapiro, Geoffrey I. [1 ]
Supko, Jeffrey [2 ]
Kharbanda, Surender [3 ]
Kufe, Donald [1 ]
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA
[3] Genus Oncol Boston, Boston, MA USA
关键词
BETA-CATENIN; PHOSPHOINOSITIDE; 3-KINASE; ACQUIRED-RESISTANCE; KINASE INHIBITOR; REGULATORY LOOP; C-SRC; GROWTH; RECEPTOR; MUTATIONS; PATHWAYS;
D O I
10.1158/1535-7163.MCT-10-1050
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small cell lung cancer (NSCLC) cells are often associated with constitutive activation of the phosphoinositide 3-kinase (PI3K) -> Akt -> mTOR pathway. The mucin 1 (MUC1) heterodimeric glycoprotein is aberrantly overexpressed in NSCLC cells and induces gene signatures that are associated with poor survival of NSCLC patients. The present results show that the MUC1 C-terminal subunit (MUC1-C) cytoplasmic domain associates with PI3K p85 in NSCLC cells. We show that inhibition of MUC1-C with cell-penetrating peptides blocks this interaction with PI3K p85 and suppresses constitutive phosphorylation of Akt and its downstream effector, mTOR. In concert with these results, treatment of NSCLC cells with the MUC1-C peptide inhibitor GO-203 was associated with downregulation of PI3K -> Akt signaling and inhibition of growth. GO-203 treatment was also associated with increases in reactive oxygen species (ROS) and induction of necrosis by a ROS-dependent mechanism. Moreover, GO-203 treatment of H1975 (EGFR L858R/T790M) and A549 (K-Ras G12S) xenografts growing in nude mice resulted in tumor regressions. These findings indicate that NSCLC cells are dependent on MUC1-C both for activation of the PI3K -> Akt pathway and for survival. Mol Cancer Ther; 10(5); 806-16. (C) 2011 AACR.
引用
收藏
页码:806 / 816
页数:11
相关论文
共 49 条
[41]   Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells [J].
Raina, Deepak ;
Ahmad, Rehan ;
Joshi, Maya Datt ;
Yin, Li ;
Wu, Zekui ;
Kawano, Takeshi ;
Vasir, Baldev ;
Avigan, David ;
Kharbanda, Surender ;
Kufe, Donald .
CANCER RESEARCH, 2009, 69 (12) :5133-5141
[42]   The MUC1 and galectin-3 oncoproteins function in a MicroRNA-dependent regulatory loop [J].
Ramasamy, Selvi ;
Duraisamy, Sekhar ;
Barbashov, Sergei ;
Kawano, Takeshi ;
Kharbanda, Surender ;
Kufe, Donald .
MOLECULAR CELL, 2007, 27 (06) :992-1004
[43]   Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma [J].
Riely, Gregory J. ;
Kris, Mark G. ;
Rosenbaum, Daniel ;
Marks, Jenifer ;
Li, Allan ;
Chitale, Dhananjay A. ;
Nafa, Khedoudja ;
Riedel, Elyn R. ;
Su, Meier H. ;
Pao, William ;
Miller, Vincent A. ;
Ladanyi, Marc .
CLINICAL CANCER RESEARCH, 2008, 14 (18) :5731-5734
[44]   Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592:: A laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy [J].
Schiller, JH ;
Adak, S ;
Feins, RH ;
Keller, SM ;
Fry, WA ;
Livingston, RB ;
Hammond, MEM ;
Wolf, B ;
Sabatini, L ;
Jett, J ;
Kohman, L ;
Johnson, DH .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :448-457
[45]   The LKB1-AMPK pathway: metabolism and growth control in tumour suppression [J].
Shackelford, David B. ;
Shaw, Reuben J. .
NATURE REVIEWS CANCER, 2009, 9 (08) :563-575
[46]   Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance [J].
Shimamura, Takeshi ;
Li, Danan ;
Ji, Hongbin ;
Haringsma, Henry J. ;
Liniker, Elizabeth ;
Borgman, Christa L. ;
Lowell, April M. ;
Minami, Yuko ;
McNamara, Kate ;
Perera, Samanthi A. ;
Zaghlul, Sara ;
Thomas, Roman K. ;
Greulich, Heidi ;
Kobayashi, Susumu ;
Chirieac, Lucian R. ;
Padera, Robert F. ;
Kubo, Shigeto ;
Takahashi, Masaya ;
Tenen, Daniel G. ;
Meyerson, Matthew ;
Wong, Kwok-Kin ;
Shapiro, Geoffrey I. .
CANCER RESEARCH, 2008, 68 (14) :5827-5838
[47]   Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways [J].
Sordella, R ;
Bell, DW ;
Haber, DA ;
Settleman, J .
SCIENCE, 2004, 305 (5687) :1163-1167
[48]   Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy [J].
Sunaga, Noriaki ;
Shames, David S. ;
Girard, Luc ;
Peyton, Michael ;
Larsen, Jill E. ;
Imai, Hisao ;
Soh, Junichi ;
Sato, Mitsuo ;
Yanagitani, Noriko ;
Kaira, Kyoichi ;
Xie, Yang ;
Gazdar, Adi F. ;
Mori, Masatomo ;
Minna, John D. .
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (02) :336-346
[49]   SH2 DOMAINS RECOGNIZE SPECIFIC PHOSPHOPEPTIDE SEQUENCES [J].
ZHOU, SY ;
SHOELSON, SE ;
CHAUDHURI, M ;
GISH, G ;
PAWSON, T ;
HASER, WG ;
KING, F ;
ROBERTS, T ;
RATNOFSKY, S ;
LECHLEIDER, RJ ;
NEEL, BG ;
BIRGE, RB ;
FAJARDO, JE ;
CHOU, MM ;
HANAFUSA, H ;
SCHAFFHAUSEN, B ;
CANTLEY, LC .
CELL, 1993, 72 (05) :767-778